you are here:

Jubilant Pharmova Ltd.


Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE700A01033 | SECTOR: Pharmaceuticals

BSE Live

Oct 22, 16:00
600.00 -11.75 (-1.92%)
  • Prev. Close


  • Open Price


  • Bid Price (Qty.)

    604.10 (36)

  • Offer Price (Qty.)

    611.75 (1137)

NSE Live

Oct 22, 15:56
604.20 -7.20 (-1.18%)
  • Prev. Close


  • Open Price


  • Bid Price (Qty.)

    604.20 (794)

  • Offer Price (Qty.)

    0.00 (0)

Company History - Jubilant Pharmova
YEAR                       EVENTS
 1978 - The Company was incorporated on 21st June, in Uttar Pradesh. 
        Company manufacture Vinyl Acetate Monomer (VAM).  The Company
        was promoted by A.B. Bofors (Swedish Multinational),
        Wires Ltd., and Mr. M.L. Bhartia.
      - The Company entered into a technical collaboration agreement
        Noble Chematur Division of A.B. Bofors, Sweden for the supply
        know-how and basic engineering for the manufacture of vinyl
        acetate monomer.
 1981 - 1,200 No. of equity shares subscribed for by the signatories
        the Memorandum of Association.  34,63,800 No. of equity and
        38,500 Pref. shares issued through a prospectus during
        1982, 19,250 Pref. shares each reserved and allotted to
        and PICUP.  6,08,370 No. of equity shares reserved and
        to Indian private promoters and their associates, 6,55,430 No.
        equity shares reserved and allotted to AB Brothers of Sweden
        22,00,000 No. of equity shares offered at par for public
        subscription.  Pref. shares redeemable during 28.5.1993/96.
 1982 - 6,93,000 Rights Equity shares issued at par in prop. 1:5
        5,52,043 shares taken up).  The remaining 1,40,357 shares
        allotted on private placement basis (including 96,800 shares
 1983 - Another technical collaboration agreement was signed with
        Decorative Products Ltd., U.K., and Reed International
        for the manufacture of high pressure emulsions i.e.,
        Acetate Emulsions.  This project was commissioned in 1985-86.
      - During November, the Company promoted `India Glycols Ltd.' to
        take up the implementation of a project to manufacture Mono
        Ethylene Glyco (MEG) at Kashipur, U.P., in technical
        collaboration with Scientific Design Co. Int., U.S.A.
        production commenced on 1st January, 1990.
 1984 - A technical collaboration agreement was signed with
        Spa of Italy for the manufacture of polyvinyl alcohol with an
        installed capacity of 2,000 tonnes per annum.  The unit was
        commissioned in July 1991, with an installed capacity of 650
        per annum.  During 1991, the capacity was doubled to 1,400
        per annum.  The Company proposed to enhance the capacity of
        2,000 MT per annum by installing additional equipment.
 1985 - Vam Leasing Ltd., and Vam Investments Ltd., were incorporated
        wholly owned subsidiaries of the Company.
 1986 - 10,06,180 No. of equity shares issued at par to financial
        institutions on conversion of loans.
 1987 - The Company decided to set up a plant to recover carbon
        in collaboration with Hydrogas Denmart a.s. of Denmark and
        manufacture to dry ice.  The plant was commissioned in 1989. 
        biogas plant was also set up in collaboration with Biotim N.V.
        Belgium as a part of energy conservation programme.
      - The Company also promoted `Insilco Ltd.' jointly with Degussa
        of West Germany for the manufacture of spray dried silica. 
        project was expected to go on stream by the middle of 1991.
      - Applications were also submitted to Government for increasing
        production capacity of vinyl acetate monomer from 10,000
        to 20,000 tonnes per annum.
      - In order to part finance the vinyl acetate monomer project,
        during January, the company privately placed with financial
        institutions, 15% non-convertible debentures worth Rs 1.00
        crores.  These debentures are redeemable at a premium of 5%
        three equal annual instalments commencing on 27th April,
      - The Company privately placed with financial institutions 14%
        non-convertible debentures worth Rs 1.50 crores.  These
        debentures are redeemable in full at a premium of 5% on 29th
        December, 1994.
 1989 - A synthetic wood adhesive Vamicol was launched in January and
        liquid and dry carbon-di-oxide (dryice) were launched in
        The company installed another new boiler of capacity 25
        steam/hour based on the fluidised bed technology to eliminate
      - The Company privately placed with financial institutions 14%
        non-convertible debentures worth Rs 10 crores.  These
        are redeemable in full at a premium of 5% on 25th June, 1996.
 1990 - The Company commissioned a plant with an installed capacity
        500 tonnes per annum for the manufacture of pyridine and
      - The Company undertook to expand the production capacities of
        vinyl acetate monomer and its intermediaries i.e., acetic
        anhydride and acetic acid.  The expanded capacities were
        commissioned in October 1990.
      - The Company privately placed 14% redeemable non-convertible
        debentures of Rs 100 each aggregating Rs 5.00 crores.  These
        debentures are redeemable at a premium of 5% in three equal
        annual instalments commencing on 11th September, 1996.
      - During the year, another 5,00,000-14% redeemable
        debentures of Rs 100 each were privately placed with a
        to redeem at a premium of 5% in three equal instalments
        commencing on 29th March, 1997.
 1992 - Ramganga Fertilizers Ltd. (RFL) was amalgamated with the
        effective 1st April, as per BIFR Scheme.  As per the scheme
        amalgamation 2,56,522 No. of equity shares of Rs 10 each were
        issued at par to the shareholders of erstwhile RFL in the
        of one equity share of the company for every 10.35 No. of
        share of Rs 10 each fully paid-up of the erstwhile RFL.
 1995 - A technical collaboration agreement was signed with Kemira
        Coatings Ltd., U.K., to manufacture wood finishes a polymer
        product.  Another agreement was also signed with M/s.
        Germany to manufacture construction chemicals in its plant at
      - The company proposed to install an additional turbine
        with a capacity of 5.5 MW in view of high and frequently
        incidence of power failure and fluctuation.  The company also
        proposed to increase the installed capacity of Pyridine &
        Picolines by 4,000 tonnes per annum to meet the increasing
        for the products.
      - 2,56,522 No. of equity shares issued to the shareholders of
        erstwhile RFL on merger of the said company with company.
 1996 - The Company proposed to open offices in Singapore to cater to
        need of S.E. Asia & China & European markets.  With a view to
        tackling the power failure and fluctuations, the company
        to instal a turbine generator with a capacity of 5.5 MW.
      - The company made a capital expenditure of Rs 26.40 crores for
        taking up projects such as Pyridene & Picolines, wood
        construction chemicals with the intention of saving valuable
        foreign Exchange.  It was also proposed to modernise its
        sulphuric acid plant.  With a view to saving energy the
        proposed to instal biogas fired boiler.
 1997 - The Company faced a sharp decline in sales realisation of
        Acid and VAM, due to a combination of the South East Asian
        financial debacle and the large capacity build up of Acetic
        and VAM in South Korean and Singapore.
      - The company has embarked on a substantial capital expenditure
        programme to enhance capacities of existing products and also
        manufacture new products.
      - Vam Organic Chemicals Ltd has registered a 8.97 per cent
        in net profit for the year ended March 31, 1997 at Rs.23.07
        crores as compared to Rs.21.17 crores in the previous year.
 1998 - Vam Organics Chemicals has introduced a specialist adhesive
        Vam Bond 2001.
      - The dry silica venture, jointly promoted by Vam Organics and
        Degussa AG of Germany with a 34 per cent stake each has not
        been doing too well.
      - The company's performance has been affected due to low
        international prices, steady increase in prices of major raw
        materials and sluggish growth in the overall market.
      - VAM Organic Chemicals Ltd (VOCL) proposes to merge group
        companies Anichem India Ltd (AIL) and Enpro Speciality
        Ltd (ESCL) with itself.
      - A planned shut-down of the fertiliser plant was undertaken for
        days in the quarter for revamping.  It also increased its
        installed capacity from 125 tonnes per day to 175 tonnes per
        for sulphuric acid.  A captive power plant of 12.45 MW was
        commissioned in July this year.
      - VAM Organic Chemicals Ltd is exploring the possibility of
        entering into areas such as sugar, speciality chemicals and
        bulk drugs.
      - The non-convertible debenture programme of Vam Organic
        Chemicals Ltd has been downgraded by ICRA to LA- LAA-.
        Vam was the largest player in the alcohol-based organic
        chemical industry with the largest capacities in the country
        for most of its products including acetic acid, acetic
        anhydride, etc.
 1999 - VAM Organic Chemicals Ltd (VOCL) has proposed to consolidate
        improve its existing position in the chemical industry in the
        current fiscal.
      - VOCL has also commissioned the units of Polychem Ltd,
        manufacturing alcohol-based chemicals in May.
      - The Company's 22,500 tonnes per annum formaldehyde plant has
        been commissioned, permitting it to export greater quantities
        of picolines and pyridines.  It has also installed new
        and increased the capacities of existing plants.
 -Enters the Bio / chemo informatics arena by setting up Jubilant
 Biosys Ltd.
 -New corporate identity: Jubilant Organosys Ltd. reflecting changed
 corporate and business profile
 -Acquires the Active Pharmaceutical Ingredients business 
 -Trading symbol of Jubilant Organosys Limited is  changed from
 -Jubliant Securites Pvt. Ltd. & Jubliant Capital Pvt. Ltd has
 acquired 4,38,068 (2.99% of total paid up capital) equity shares.
 -Mr. H K Khan (Retd. IAS) has been appointed as additional director
 with effect from November 05, 2003 on the Board.
 -Jubilant Organosys Limited has informed that the Board of Directors
 at their meeting held on January 9, 2004 have approved for voluntary
 delisting of equity shares of the Company from The Delhi Stock
 Exchange Association Limited, The Calcutta Stock Exchange Association
 Limited, Kolkata and the Uttar Pradesh Stock Exchange Association
 Limited subject to the approval of shareholders by special
 -Jubilant Organosys acquires generic pharma Companies in Europe
 -Jubilant Organosys signs international contracts worth US$ 60
 million in CRAMS for the year 2007
 -Acquired pharmaceutical company in USA involved in off patent drug
 development and supply, and owns US FDA approved manufacturing
 facility for solid dosage forms.
 -Acquires full service Clinical Research Organization in USA involved
 in providing clinical research services, data management,
 biostatistics and contract staffing.
 -Acquires Target Research Associates, Inc., renamed Clinsys Inc.; a
 US based Clinical Research Organisation (CRO)
 -Acquires Trinity Laboratories, Inc. and its wholly owned subsidiary,
 Trigen Laboratories, Inc., renamed Jubilant Pharmaceuticals, Inc., a
 generic pharmaceutical company in USA having a US FDA approved
 formulations manufacturing facility
 -Enters Clinsys Clinical Research Ltd. business by setting up wholly
 owned subsidiary Jubilant Clinsys Ltd.
 -Selected as one of the top 25 companies for Institute of Company
 Secretaries of India National Award for Excellence in Corporate
 -Finalist in Golden Peacock Award for Excellence in Corporate
 -Company has splits its Face value of Shares from Rs 5 to Re 1
 -Jubilant Organosys Ltd has acquired 100% equity stake in
 Hollister-Stier Laboratories LLC, USA, engaged in high growth
 Injectable contract manufacturing and well established and stable
 Allergy Immunotherapy businesses.
 -Acquires Hollister Stier Laboratories in USA, a contract
 manufacturer of Sterile injectable vials and allergenic extracts.
 -Acquires DRAXIS Specialty Pharmaceuticals, Inc. Canada, a contract
 manufacturer of sterile & non-sterile products and
 -Acquires Speciality Molecules Pvt. Ltd. Engaged in the manufacturing
 of Fine Chemicals used by Life Science Industry including pharma, agro
 & cosmetic industry.
 -Jubilant Organosys and Lilly form Drug development joint venture
 - Uttar Pradesh-based pharma major Jubilant Organosys Ltd (JOL) has
 secured new contracts worth $92 million (Rs.3.7 billion). The
 contracts have been signed under Customs Research and Manufacturing
 Services (CRAMS). Besides marketing its products in the regulated
 markets of the US, Europe and Japan, the company has managed to make
 forays into China, said a statement of JOL.
 -Jubilant enters into multiple Drug discovery partnerships with
 leading pharma and biotech -companies such as AstraZeneca, Orion,
 Endo pharmaceuticals & BioLeap and also extends its collaboration
 with Lilly for five years.
 -Jubilant enters into drug development collaborations with academia,
 University of Alabama at Birmingham and Southern Research Institute
 (USA) and Duke University (Singapore).
 -Jubilant Kalpataru  120 bed super specialty hospital at Barasat,
 Kolkata, India inaugurated by Honble Minister of Finance Shri Pranab
 -ET  IMEA 2009 Platinum Award by Frost & Sullivan, in the
 Pharmaceutical category for the API facility at Nanjangud
 -Best CFO (FMCG, Health and Retail Sector) to Mr. R. Sankaraiah by
 Institute of Chartered Accountants of India in January, 2010
 - Jubilant Organosys Ltd has appointed Mr. Shardul S. Shroff as
 Additional Director of the Company with effect from March 15, 2010.
 - Jubilant Organosys Ltd has signed  a USD 51 million CRAMS contract
 with a leading Life Sciences Company
 -The Company has changed from Jubilant Organosys Ltd to JUBILANT LIFE
 -Mr. Shardul S. Shroff has been appointed as Additional Director of
 the Company.
 -Jubilant Life Sciences Ltd has announced another successful delivery
 of an early stage milestone in the Pain therapeutic area.
 -Jubilant Org - Jubilant sets up global scale capacities for Symtet -
 developed through 
 -JubilantLife - announced today that they have achieved an early
 stage milestone in one of their collaborative programs with Chadds
 -Jubilant HollisterStier Announces Multi-Million Dollar Award for the
 manufacture of Sterile Parenteral Products.
 -Jubilant SEZ at Bharuch, inaugurated by Shri Narendra Modi, Honble
 Chief Minister of Gujarat.
 - Jubilant Life Sciences receives prestigious NDTV Profit Business
 Leadership Award 2012 for Corporate Social Responsibility.
 - Jubilant Life Sciences receives ANDA approval for Quetiapine
 Fumarate Tablet
 -Jubilant Life Sciences declared winner of Supply Chain Excellence
 Awards at 7th Express, Logistics & Supply Chain Leadership Awards
 - Jubilant Life Scienc - Results of Tender Offer for acquisition of
 minority shares of Cadista Holdings Inc.
 -  Board recommended a Dividend of Rs.3 per equity shares of Rs.1 
 -Jubilant Life Sciences wins Excellence Awards at India Pharma
 Awards 2014
 -Jubilant Life Sciences conferred with Golden Peacock Business
 Excellence Award-2014
 -Gold Award in Ankleshwar Chapter Convention on Quality Concepts 2015
 -Two Honors at the 10th Annual CIO100 Awards by CIO Magazine - CIO100
 Innovation Architect Special Awards 2015 and Versatile 100honorees
 -Golden Peacock National Quality Award for Quality
 -Dataquest Business Technology Awards for Best IT Implementation in
 Analytics, Mobility, Cloud, ERP/CSM/CRM
 -ASSOCHAMs Responsible Organization Excellence Award 2014-15
 -50 Most Talented Sustainability Leaders Award
 -15th Annual Greentech Environment Award 2014 - Gold Category winner
 under Chemicals and Pharmaceutical sector - Gajraula plant, India
 -I.C.O.N.I.C IDC Insights Award, under Health and Life Sciences
 - Jubilant Life Sciences Limited won the Sustainability Award for
 Best Green Process in Chemical sector of FICCI Chemicals &
 Petrochemicals Awards, 2016. 
 -Jubilant gets USFDA nod for generic anti-fungal capsules.
 -Jubilant Life eyes speciality pharma biz acquisition in US.
 -Jubilant completes acquisition of Radiopharmacy business of Triad.
 -Second Awards under the category of Basic Inorganic, Organic
 Chemicals including Agro Chemicals for the outstanding export
 performance of the year 2015-16 by CHEMEXCIL.
 -'Most Consistent IR (Investor Relations) Practice in the country'
 Award for the year 2017 instituted by IR Society of India
 -Green tech Environment Award 2017 received by Nanjangud Plant
 Jubilant Life Sciences Ltd, Gajraula awarded with CII 17th National
 -Award for Excellence in Energy Award 2016 In Category of